PRVB - プロベンション・バイオ (Provention Bio Inc.)

PRVBのニュース

   Provention Bio to Present at Upcoming Virtual Investor Conferences  2020/09/08 11:30:00 PR Newswire
RED BANK, N.J., Sept. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at three upcoming virtual investor conferences in September: The…
   Provention Bio Reports Second Quarter 2020 Financial Results and Provides Business Update  2020/08/06 11:00:00 PR Newswire
OLDWICK, N.J., Aug. 6, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the second quarter ended June 30, 2020 and provided a business…
   In-house counsel on the move: Rite Aid taps new GC as pharma, tech players shuffle top lawyers  2020/08/05 22:41:26 Reuters
Three companies with relatively pandemic-proof businesses - pharmacy and drugstore Rite Aid, online textbook rental company Chegg Inc and pharmaceutical company Provention Bio Inc - tapped new top lawyers this week.
   Provention Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020  2020/07/30 11:00:00 PR Newswire
OLDWICK, N.J., July 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2020 financial results on Thursday, August…
   Why This Under-the-Radar Biotech Stock Could Skyrocket  2020/07/02 13:15:00 The Motley Fool
Provention Bio is developing a drug that could delay the onset of diabetes, and if it's successful, the company's stock could soar.
   Provention Bio (PRVB) Soars: Stock Adds 6.4% in Session  2020/04/01 13:09:00 Zacks Investment Research
Provention Bio (PRVB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
   Provention Bio to Present at Upcoming Conferences  2020/02/19 12:00:00 PR Newswire
OLDWICK, N.J., Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at two upcoming conferences: The 9th Annual SVB…
   Provention Bio Appoints Jason Hoitt as Chief Commercial Officer  2020/01/08 12:00:00 PR Newswire
/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated…
   Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA  2019/12/12 12:00:00 PR Newswire
OLDWICK, N.J., Dec. 12, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it completed a Type B multidisciplinary meeting with the U.S. Food and Drug…
   Provention Bio Reports Third Quarter 2019 Financial Results  2019/11/05 21:05:00 PR Newswire
OLDWICK, N.J., Nov. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2019. "The PRV-031…
   Provention Bio to Present at Upcoming Conferences  2020/02/19 12:00:00 PR Newswire
OLDWICK, N.J., Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at two upcoming conferences: The 9th Annual SVB…
   Provention Bio Appoints Jason Hoitt as Chief Commercial Officer  2020/01/08 12:00:00 PR Newswire
/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated…
   Provention Bio Reiterates Regulatory Guidance for PRV-031 (Teplizumab) Following Meeting with the FDA  2019/12/12 12:00:00 PR Newswire
OLDWICK, N.J., Dec. 12, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it completed a Type B multidisciplinary meeting with the U.S. Food and Drug…
   Provention Bio Reports Third Quarter 2019 Financial Results  2019/11/05 21:05:00 PR Newswire
OLDWICK, N.J., Nov. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2019. "The PRV-031…
   The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering  2019/06/11 11:34:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Stellar Biotechnologies Inc (NASDAQ: EDSA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Kodiak Sciences Inc (NASDAQ: KOD ) Provention Bio Inc (NASDAQ: PRVB )( announced positive results for its PRV-031 in at-risk Type 1 diabetes patient) Down In The Dumps (Biotech stocks hitting 52-week lows on June 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Endo International PLC (NASDAQ: ENDP ) Insys Therapeutics Inc (NASDAQ: INSY )( filed for bankruptcy protection) Novavax, Inc (NASDAQ: NVAX )(reacted to the news of FDA requiring an additional Phase 3 study for its respiratory syncytial virus vaccine ResVax) Sensus Healthcare Inc (NASDAQ: SRTS ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) T2 Biosystems Inc (NASDAQ: TTOO ) Teligent Inc (NASDAQ: TLGT ) Stock In Focus Eli Lily Presents Positive Long-term Efficacy Data For Psoriasis Treatment Eli Lilly And Co (NYSE: LLY ) said it will present at the World Congress of Dermatology positive five-year Phase 3 data for Taltz in patients with moderate-to-severe plaque psoriasis.

calendar